Goldman Sachs Group Inc Apellis Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 195,066 shares of APLS stock, worth $6.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

195,066

Previous 146,926 32.76%

Holding current value

$6.46 Million

Previous $5.64 Million 0.2%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $1.39 Million - $1.98 Million	48,140 Added 32.76%	195,066 $5.63 Million
Q2 2024 Aug 13, 2024	SELL	$38.07 - $59.71 $6.57 Million - $10.3 Million	-172,550 Reduced 54.01%	146,926 $5.64 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $492,583 - $644,475	8,893 Added 2.86%	319,476 $18.8 Million
Q4 2023 Feb 13, 2024	SELL	$37.14 - $64.82 $787,739 - $1.37 Million	-21,210 Reduced 6.39%	310,583 $18.6 Million
Q3 2023 May 14, 2024	BUY	$23.65 - $89.22 $501,616 - $1.89 Million	21,210 Added 6.83%	331,793 $12.6 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $7.17 Million - $27 Million	-303,104 Reduced 47.74%	331,793 $12.6 Million
Q2 2023 May 14, 2024	SELL	$76.68 - $93.31 $2.17 Million - $2.64 Million	-28,298 Reduced 4.27%	634,897 $57.8 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $2.17 Million - $2.64 Million	-28,298 Reduced 4.27%	634,897 $57.8 Million
Q1 2023 May 14, 2024	SELL	$46.59 - $66.96 $18.6 Million - $26.7 Million	-398,508 Reduced 37.53%	663,195 $43.7 Million
Q1 2023 May 11, 2023	SELL	$46.59 - $66.96 $18.6 Million - $26.7 Million	-398,508 Reduced 37.53%	663,195 $43.7 Million
Q4 2022 May 14, 2024	BUY	$43.24 - $61.04 $4.5 Million - $6.35 Million	104,025 Added 10.86%	1,061,703 $54.9 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $4.5 Million - $6.35 Million	104,025 Added 10.86%	1,061,703 $54.9 Million
Q3 2022 May 14, 2024	BUY	$44.76 - $69.66 $6.59 Million - $10.3 Million	147,279 Added 18.17%	957,678 $65.4 Million
Q3 2022 Nov 10, 2022	BUY	$44.76 - $69.66 $6.59 Million - $10.3 Million	147,279 Added 18.17%	957,678 $65.4 Million
Q2 2022 May 14, 2024	BUY	$35.07 - $59.21 $17.5 Million - $29.6 Million	499,816 Added 160.93%	810,399 $36.6 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $10.9 Million - $18.4 Million	310,145 Added 62.0%	810,399 $36.6 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $77,019 - $117,548	2,172 Added 0.44%	500,254 $25.4 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $16.1 Million - $25.8 Million	-525,088 Reduced 51.32%	498,082 $23.5 Million
Q3 2021 Nov 10, 2021	BUY	$31.4 - $69.84 $32.1 Million - $71.5 Million	1,023,170 New	1,023,170 $33.7 Million

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Apellis Pharmaceuticals, Inc. Transaction History